{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT00790413",
      "OrgStudyIdInfo": {
        "OrgStudyId": "385/2005"
      },
      "Organization": {
        "OrgFullName": "Lund University Hospital",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Haploidentical Stem Cell Transplantation in Neuroblastoma",
      "OfficialTitle": "High-dose MIBG With Subsequent Transplantation of Haploidentical Stem Cells in Children With Therapy Resistant Neuroblastoma"
    },
    "StatusModule": {
      "StatusVerifiedDate": "February 2021",
      "OverallStatus": "Active, not recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "August 2005"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "December 31, 2022",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "December 31, 2022",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "November 12, 2008",
      "StudyFirstSubmitQCDate": "November 12, 2008",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "November 13, 2008",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "February 17, 2021",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "February 21, 2021",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Principal Investigator",
        "ResponsiblePartyInvestigatorFullName": "Jacek Toporski",
        "ResponsiblePartyInvestigatorTitle": "MD, PhD",
        "ResponsiblePartyInvestigatorAffiliation": "Lund University Hospital"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Lund University Hospital",
        "LeadSponsorClass": "OTHER"
      }
    },
    "OversightModule": {},
    "DescriptionModule": {
      "BriefSummary": "Children with primary resistant or relapsed neuroblastoma who do not achieve remission with conventional chemotherapy have extremely dismal prognosis. A novel treatment strategy combining tumor targeted radioisotope treatment with metaiodobenzylguanidine (MIBG) and immunotherapeutic effect of haploidentical stem cell transplantation (haploSCT) followed by low-dose donor lymphocyte infusions will be piloted. The use of the isotope is aimed to decrease pre-transplant tumour burden. Reduced intensity conditioning containing Fludarabine, Thiotepa and Melfalan will enable sustained engraftment as well as will serve as additional anti-tumor treatment. A prompt natural killer (NK)-cell mediated tumour control may be achieved by haploidentical stem cell transplantation. The investigators hypothesize that tumour cells potentially evading NK-cell mediated immunity may be targeted by infused donor T-cells and eliminated by either MHC-dependent manner or through a bystander effect. The possible graft versus tumor effect will be evaluated in children with therapy resistant neuroblastoma."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Neuroblastoma"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Radiotherapy",
          "Immunotherapy",
          "Hematopoietic Stem Cell Transplantation"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Early Phase 1"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "15",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "High-dose MIBG with haploidentical stem cell transplantation",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "High-dose MIBG followed by Fludarabine, Thiotepa and Melfalan as conditioning Before haploidentical transplantation of T-cell depleted graft",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: iodine I 131 metaiodobenzylguanidine",
                "Drug: Fludarabine",
                "Drug: Thiotepa",
                "Procedure: T-cell depletion",
                "Procedure: Haploidentical stem cell transplantation",
                "Procedure: Donor Lymphocyte Infusion",
                "Drug: Rituximab",
                "Procedure: Co-transplantation of mesenchymal stem cells"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Drug",
            "InterventionName": "iodine I 131 metaiodobenzylguanidine",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "High-dose MIBG with haploidentical stem cell transplantation"
              ]
            }
          },
          {
            "InterventionType": "Drug",
            "InterventionName": "Fludarabine",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "High-dose MIBG with haploidentical stem cell transplantation"
              ]
            }
          },
          {
            "InterventionType": "Drug",
            "InterventionName": "Thiotepa",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "High-dose MIBG with haploidentical stem cell transplantation"
              ]
            }
          },
          {
            "InterventionType": "Procedure",
            "InterventionName": "T-cell depletion",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "High-dose MIBG with haploidentical stem cell transplantation"
              ]
            }
          },
          {
            "InterventionType": "Procedure",
            "InterventionName": "Haploidentical stem cell transplantation",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "High-dose MIBG with haploidentical stem cell transplantation"
              ]
            }
          },
          {
            "InterventionType": "Procedure",
            "InterventionName": "Donor Lymphocyte Infusion",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "High-dose MIBG with haploidentical stem cell transplantation"
              ]
            }
          },
          {
            "InterventionType": "Drug",
            "InterventionName": "Rituximab",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "High-dose MIBG with haploidentical stem cell transplantation"
              ]
            }
          },
          {
            "InterventionType": "Procedure",
            "InterventionName": "Co-transplantation of mesenchymal stem cells",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "High-dose MIBG with haploidentical stem cell transplantation"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Engraftment rate",
            "PrimaryOutcomeTimeFrame": "day 100"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Overall survival",
            "SecondaryOutcomeTimeFrame": "1 year"
          },
          {
            "SecondaryOutcomeMeasure": "Immunological reconstitution",
            "SecondaryOutcomeTimeFrame": "day 100"
          },
          {
            "SecondaryOutcomeMeasure": "Incidence of acute graft versus host disease",
            "SecondaryOutcomeTimeFrame": "day 100"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nRefractory neuroblastoma (any chemo/radiosensitive stable disease)\nRelapse incl. autologous HSCT 3 m earlier\nPrimary induction failure\nCardiac output SF ≥25%\nCreatinine clearance ≥40 cc/min/1.73 m2\nPerformance score of ≥50% (Lansky or Karnofsky)\nAvailable haploidentical family donor, aged ≥18 yrs, HIV-neg\n\nExclusion Criteria:\n\nRapidly progressive disease\nPregnancy",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "6 Months",
      "MaximumAge": "21 Years",
      "StdAgeList": {
        "StdAge": [
          "Child",
          "Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Jacek Toporski, MD, PhD",
            "OverallOfficialAffiliation": "Lund University Hospital, Department of Pediatric Oncology",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Lund University Hospital, Department of Pediatric Oncology and Bone Marrow Transplantation",
            "LocationCity": "Lund",
            "LocationZip": "221 85",
            "LocationCountry": "Sweden"
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "12815485",
            "ReferenceType": "background",
            "ReferenceCitation": "Inoue M, Nakano T, Yoneda A, Nishikawa M, Nakayama M, Yumura-Yagi K, Sakata N, Yasui M, Okamura T, Kawa K. Graft-versus-tumor effect in a patient with advanced neuroblastoma who received HLA haplo-identical bone marrow transplantation. Bone Marrow Transplant. 2003 Jul;32(1):103-6."
          },
          {
            "ReferencePMID": "16421427",
            "ReferenceType": "background",
            "ReferenceCitation": "Matthay KK, Tan JC, Villablanca JG, Yanik GA, Veatch J, Franc B, Twomey E, Horn B, Reynolds CP, Groshen S, Seeger RC, Maris JM. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study. J Clin Oncol. 2006 Jan 20;24(3):500-6."
          },
          {
            "ReferencePMID": "15650233",
            "ReferenceType": "background",
            "ReferenceCitation": "Prigione I, Corrias MV, Airoldi I, Raffaghello L, Morandi F, Bocca P, Cocco C, Ferrone S, Pistoia V. Immunogenicity of human neuroblastoma. Ann N Y Acad Sci. 2004 Dec;1028:69-80. Review."
          },
          {
            "ReferencePMID": "14504825",
            "ReferenceType": "background",
            "ReferenceCitation": "Neal ZC, Imboden M, Rakhmilevich AL, Kim KM, Hank JA, Surfus J, Dixon JR, Lode HN, Reisfeld RA, Gillies SD, Sondel PM. NXS2 murine neuroblastomas express increased levels of MHC class I antigens upon recurrence following NK-dependent immunotherapy. Cancer Immunol Immunother. 2004 Jan;53(1):41-52. Epub 2003 Sep 18."
          },
          {
            "ReferencePMID": "15897905",
            "ReferenceType": "background",
            "ReferenceCitation": "Raffaghello L, Prigione I, Bocca P, Morandi F, Camoriano M, Gambini C, Wang X, Ferrone S, Pistoia V. Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications. Oncogene. 2005 Jul 7;24(29):4634-44."
          },
          {
            "ReferencePMID": "17080334",
            "ReferenceType": "background",
            "ReferenceCitation": "Lang P, Pfeiffer M, Müller I, Schumm M, Ebinger M, Koscielniak E, Feuchtinger T, Föll J, Martin D, Handgretinger R. Haploidentical stem cell transplantation in patients with pediatric solid tumors: preliminary results of a pilot study and analysis of graft versus tumor effects. Klin Padiatr. 2006 Nov-Dec;218(6):321-6."
          },
          {
            "ReferencePMID": "19660720",
            "ReferenceType": "result",
            "ReferenceCitation": "Toporski J, Garkavij M, Tennvall J, Ora I, Gleisner KS, Dykes JH, Lenhoff S, Juliusson G, Scheding S, Turkiewicz D, Békássy AN. High-dose iodine-131-metaiodobenzylguanidine with haploidentical stem cell transplantation and posttransplant immunotherapy in children with relapsed/refractory neuroblastoma. Biol Blood Marrow Transplant. 2009 Sep;15(9):1077-85. doi: 10.1016/j.bbmt.2009.05.007. Epub 2009 Jul 8."
          },
          {
            "ReferencePMID": "29307718",
            "ReferenceType": "result",
            "ReferenceCitation": "Illhardt T, Toporski J, Feuchtinger T, Turkiewicz D, Teltschik HM, Ebinger M, Schwarze CP, Holzer U, Lode HN, Albert MH, Gruhn B, Urban C, Dykes JH, Teuffel O, Schumm M, Handgretinger R, Lang P. Haploidentical Stem Cell Transplantation for Refractory/Relapsed Neuroblastoma. Biol Blood Marrow Transplant. 2018 May;24(5):1005-1012. doi: 10.1016/j.bbmt.2017.12.805. Epub 2018 Jan 4."
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000009447",
            "ConditionMeshTerm": "Neuroblastoma"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000018241",
            "ConditionAncestorTerm": "Neuroectodermal Tumors, Primitive, Peripheral"
          },
          {
            "ConditionAncestorId": "D000018242",
            "ConditionAncestorTerm": "Neuroectodermal Tumors, Primitive"
          },
          {
            "ConditionAncestorId": "D000018302",
            "ConditionAncestorTerm": "Neoplasms, Neuroepithelial"
          },
          {
            "ConditionAncestorId": "D000017599",
            "ConditionAncestorTerm": "Neuroectodermal Tumors"
          },
          {
            "ConditionAncestorId": "D000009373",
            "ConditionAncestorTerm": "Neoplasms, Germ Cell and Embryonal"
          },
          {
            "ConditionAncestorId": "D000009370",
            "ConditionAncestorTerm": "Neoplasms by Histologic Type"
          },
          {
            "ConditionAncestorId": "D000009369",
            "ConditionAncestorTerm": "Neoplasms"
          },
          {
            "ConditionAncestorId": "D000009375",
            "ConditionAncestorTerm": "Neoplasms, Glandular and Epithelial"
          },
          {
            "ConditionAncestorId": "D000009380",
            "ConditionAncestorTerm": "Neoplasms, Nerve Tissue"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M11543",
            "ConditionBrowseLeafName": "Neuroblastoma",
            "ConditionBrowseLeafAsFound": "Neuroblastoma",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M18997",
            "ConditionBrowseLeafName": "Neuroectodermal Tumors",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M19540",
            "ConditionBrowseLeafName": "Neuroectodermal Tumors, Primitive",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M19539",
            "ConditionBrowseLeafName": "Neuroectodermal Tumors, Primitive, Peripheral",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M19599",
            "ConditionBrowseLeafName": "Neoplasms, Neuroepithelial",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11470",
            "ConditionBrowseLeafName": "Neoplasms, Germ Cell and Embryonal",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11467",
            "ConditionBrowseLeafName": "Neoplasms by Histologic Type",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11472",
            "ConditionBrowseLeafName": "Neoplasms, Glandular and Epithelial",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11477",
            "ConditionBrowseLeafName": "Neoplasms, Nerve Tissue",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T4085",
            "ConditionBrowseLeafName": "Neuroblastoma",
            "ConditionBrowseLeafAsFound": "Neuroblastoma",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "T4092",
            "ConditionBrowseLeafName": "Neuroepithelioma",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC04",
            "ConditionBrowseBranchName": "Neoplasms"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionMeshList": {
        "InterventionMesh": [
          {
            "InterventionMeshId": "D000069283",
            "InterventionMeshTerm": "Rituximab"
          },
          {
            "InterventionMeshId": "C000024352",
            "InterventionMeshTerm": "Fludarabine"
          },
          {
            "InterventionMeshId": "D000013852",
            "InterventionMeshTerm": "Thiotepa"
          },
          {
            "InterventionMeshId": "D000019797",
            "InterventionMeshTerm": "3-Iodobenzylguanidine"
          }
        ]
      },
      "InterventionAncestorList": {
        "InterventionAncestor": [
          {
            "InterventionAncestorId": "D000074322",
            "InterventionAncestorTerm": "Antineoplastic Agents, Immunological"
          },
          {
            "InterventionAncestorId": "D000000970",
            "InterventionAncestorTerm": "Antineoplastic Agents"
          },
          {
            "InterventionAncestorId": "D000007155",
            "InterventionAncestorTerm": "Immunologic Factors"
          },
          {
            "InterventionAncestorId": "D000045505",
            "InterventionAncestorTerm": "Physiological Effects of Drugs"
          },
          {
            "InterventionAncestorId": "D000018501",
            "InterventionAncestorTerm": "Antirheumatic Agents"
          },
          {
            "InterventionAncestorId": "D000045504",
            "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
          },
          {
            "InterventionAncestorId": "D000007166",
            "InterventionAncestorTerm": "Immunosuppressive Agents"
          },
          {
            "InterventionAncestorId": "D000018906",
            "InterventionAncestorTerm": "Antineoplastic Agents, Alkylating"
          },
          {
            "InterventionAncestorId": "D000000477",
            "InterventionAncestorTerm": "Alkylating Agents"
          },
          {
            "InterventionAncestorId": "D000019653",
            "InterventionAncestorTerm": "Myeloablative Agonists"
          },
          {
            "InterventionAncestorId": "D000004791",
            "InterventionAncestorTerm": "Enzyme Inhibitors"
          },
          {
            "InterventionAncestorId": "D000019275",
            "InterventionAncestorTerm": "Radiopharmaceuticals"
          }
        ]
      },
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M373",
            "InterventionBrowseLeafName": "Rituximab",
            "InterventionBrowseLeafAsFound": "Test",
            "InterventionBrowseLeafRelevance": "high"
          },
          {
            "InterventionBrowseLeafId": "M283219",
            "InterventionBrowseLeafName": "Fludarabine",
            "InterventionBrowseLeafAsFound": "Medical",
            "InterventionBrowseLeafRelevance": "high"
          },
          {
            "InterventionBrowseLeafId": "M225481",
            "InterventionBrowseLeafName": "Fludarabine phosphate",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M9640",
            "InterventionBrowseLeafName": "Iodine",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M229687",
            "InterventionBrowseLeafName": "Cadexomer iodine",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M10693",
            "InterventionBrowseLeafName": "Melphalan",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M15767",
            "InterventionBrowseLeafName": "Thiotepa",
            "InterventionBrowseLeafAsFound": "One year",
            "InterventionBrowseLeafRelevance": "high"
          },
          {
            "InterventionBrowseLeafId": "M20845",
            "InterventionBrowseLeafName": "3-Iodobenzylguanidine",
            "InterventionBrowseLeafAsFound": "Necrotic",
            "InterventionBrowseLeafRelevance": "high"
          },
          {
            "InterventionBrowseLeafId": "M1346",
            "InterventionBrowseLeafName": "Antineoplastic Agents, Immunological",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M9353",
            "InterventionBrowseLeafName": "Immunologic Factors",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M19757",
            "InterventionBrowseLeafName": "Antirheumatic Agents",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M9364",
            "InterventionBrowseLeafName": "Immunosuppressive Agents",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M20095",
            "InterventionBrowseLeafName": "Antineoplastic Agents, Alkylating",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M2972",
            "InterventionBrowseLeafName": "Alkylating Agents",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M20411",
            "InterventionBrowseLeafName": "Radiopharmaceuticals",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "ANeo",
            "InterventionBrowseBranchName": "Antineoplastic Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "ARhu",
            "InterventionBrowseBranchName": "Antirheumatic Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          },
          {
            "InterventionBrowseBranchAbbrev": "Micro",
            "InterventionBrowseBranchName": "Micronutrients"
          },
          {
            "InterventionBrowseBranchAbbrev": "Infe",
            "InterventionBrowseBranchName": "Anti-Infective Agents"
          }
        ]
      }
    }
  }
}